VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease. by Silvestris F et al.
VEINCTR–N, an Immunogenic Epitope of Fas
(CD95/Apo-I), and Soluble Fas Enhance T-cell 
Apoptosis in vitro. II. Functional Analysis 
and Possible Implications in HIV-1 Disease
Franco Silvestris, Paola Cafforio, Marco Tucci, Annalisa Del Prete,
and Franco Dammacco
Department of Biomedical Sciences and Human Oncology, University of Bari,
Section of Internal Medicine, Bari, Italy
Accepted April 15, 2000.
Introduction
Antibodies to Fas (CD95/Apo-I) that have an
agonist effect on apoptosis of activated T cells
Abstract
Background: Recent studies indicate that soluble
Fas (sFas) may modulate T-cell apoptosis, since it
inhibits Fas-ligand (Fas-L)-mediated cytotoxicity in
vitro. Here, we explored whether the soluble recep-
tor and its major immunogenic domain, namely
VEINCTR–N, interfered with apoptosis of T cells
from human immunodeficiency virus-type 1 (HIV-
1) subjects showing serum elevations of both the
soluble receptor and anti-Fas antibodies, and with
that of several T-cell lines.
Materials and Methods: Both proliferation 
and apoptosis extent of T cells from 16 HIV-1
patients showing serum anti-VEINCTR–N immu-
noglobulin G (IgG) and 15 controls were tested 
after incubation with sFas and three 8-mer pepti-
des of its first consensus sequence that included 
VEINCTR–N. Several cell lines were also investi-
gated by flow cytometry for their expression of 
Ki-67, the APO2.7-related mitochondrial protein,
and the annexin-V. In addition, we evaluated the 
expression of Fas-L and caspases FLICE, CPP32 
and ICE either by flow cytometry, immunoblotting,
and/or reverse transcription polymerase chain reac-
tion (RT-PCR).
Results: Cell proliferation in cultures from both
patients and controls was affected significantly by
sFas and VEINCTR–N. However, a prevalent increase
of the subdiploid DNA-containing cell population
occurred within these cultures. Similarly, Jurkat,
CEM cells, and a mouse WR19L transformant over-
expressing native human Fas underwent prompt
apoptosis, which was detected as enlargement of
APO2.7-reactive and annexin-V-positive popula-
tions. By exploring the Fas pathway in Jurkat cells,
we found that both apoptosis inducers acted through
Fas, since Fas-L, as well as CPP32 and FLICE were
activated. By contrast, ICE was up-regulated only in
control cells treated with tumor necrosis factor  (TNF).
Conclusions: These data suggest that the soluble
molecular forms of Fas prime cell death in Fas-
positive cells. Therefore, the shedding of high amounts
of sFas in HIV-1 disease is possibly entrusted with
amplification of the death execution program by cells
functionally exhausted and committed to die. It is
conceivable that the appearance of anti-Fas anti-
bodies reflects an attempt by the immune system to
neutralize these effective forms of the receptor and
its structurally degraded domains, such as VEINCTR–N.
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during human immunodeficiency virus-type 1
(HIV-1) infection have been described by
ourselves (1) and others (2). These antibodies
play a role in the depletion of CD4 lympho-
cytes that define its progression to AIDS. Their
occurrence is usually paralleled by severe lym-
phopenia (3). They were previously thought to
be elicited by molecular mimicry of the gp120
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V3 loop (4) exhibiting VEINCTR–N, a short
domain also shared by the extracellular portion
of Fas (5,6). Our recent data, however, suggest
a peculiar conformational immunogenicity of
this epitope (7). It is structurally located within
the first consensus sequence of members of the
tumor necrosis factor (TNF) receptor family (5,8)
and shows multiple disulphide bonds. In addi-
tion, significant levels of immunoglobulin G
(IgG) to VEINCTR–N have been found to corre-
late with serum elevations of soluble Fas (sFas)
(7). Further work from different groups of
investigators provided evidence that serum
titers of sFas may be increased in early (2,9), as
well as in advanced, HIV-1 infection (10,13).
The shedding of membrane receptors by ac-
tivated T cells has been stressed when describ-
ing the serologic increase of soluble forms of 
human leucocyte antigen (HLA) class I and II
molecules (14,15); T cell receptor (TCR) multiple
chains (16); members of the TNF receptor family,
including Fas and Fas-ligand (Fas-L) in a num-
ber of inflammatory diseases, allografts, autoim-
mune diseases (17); and HIV-1 infection (18,19).
Most experimental data indicate that, although
several soluble receptors may even occur in
healthy individuals (15,20), increased serum
levels are associated prevalently with their per-
sistent activation in these diseases. Clinical stud-
ies have shown that, in parallel with both
chronic activation and deregulated apoptosis in
patients with systemic lupus erythematosus
(SLE) or other autoimmune disorders, signifi-
cant elevations of sFas and sFas-L are detectable,
in particular during the active stages (17,21), and
in relation to the HLA status (22).
The physiologic function(s) of these soluble
receptors is not completely clarified. Enhanced
serum sFas-L, indeed, has been proposed as a
disease-marker in certain lymphoproliferative
disorders of the cytotoxic cell lineage (24);
whereas, the increase of sFas parallels progres-
sion in several B- and T-cell leukemias (25,26).
Additional studies propose that the membrane-
shedding of Fas by activated cells could imply 
a molecular mechanism to prevent their apopto-
sis by neutralizing Fas-L of cytotoxic cells (27).
This role of apoptosis blocker (28) also has been
attributed to splicing variants of sFas, which
are secreted by phytohemagglobinin (PHA)-acti-
vated mononuclear cells from healthy individu-
als and by human T-cell lines. Apoptosis block-
ers interfere with their apoptosis induced in
vitro by the prototypic agonist anti-Fas mono-
clonal antibody (MoAb) from clone CH-11 (33).
However, the role of the sFas and sFas-L in
HIV-1 disease is still controversial. Elevated
serum levels of both receptors draw attention to
the substantial deregulation of T-cell apoptosis
during infection (30,31). Even so, sFas in sera
from HIV-1-infected children with no evidence
of progression to AIDS is suspected to inhibit
the apoptosis of CD4 cells promoted by anti-
HIV-1-specific cytotoxic T lymphocytes (CTLs),
thus interpreting their stable values during
early disease (9). Conversely, similar elevations
of sFas have been correlated with the massive 
T-cell apoptosis observed in advanced infection
(10,13), suggesting that sFas is somehow impli-
cated in the consistent cell death of exhausted
cells. It is conceivable that cells committed to
die by apoptosis as a result of their chronic acti-
vation during infection solubilize Fas with the
potential effect of shedding the death signal and
amplifying the execution program.
We previously interpreted the humoral re-
sponse to VEINCTR–N in advanced disease as
a potential result of the high levels of circulat-
ing sFas (7). The present study investigates the
effect of sFas and its domains related to
VEINCTR–N, on T-cell proliferation and apop-
tosis. Our results indicate that sFas and its im-
munogenic epitope directly prime T cells from
HIV-1-infected patients and Fas-positive T-cell
lines for apoptosis. Thus, our data emphasize
that sFas should be regarded as an amplifier,
rather than a blocker of apoptosis.
Materials and Methods
Peripheral T-cell Cultures and Cell Lines
Sixteen HIV-1 patients with serum positivity
to VEINCTR–N and 15 uninfected individuals
provided blood samples following the approval
of the study by the ethical committee of the Uni-
versity of Bari Medical School. Peripheral T
lymphocytes were prepared by Ficoll-Hypaque
centrifugation, removal of adherent cells, incu-
bation with sheep red cells, and subsequent
gradient centrifugation to discharge the non-E-
rosetting cells. Phenotyping was performed by
flow cytometry, using a panel of fluorescein
isothiocyanate (FITC) or phycoerythrin (PE)-
conjugated MoAbs to CD3, CD4, and CD8
markers in a fluorescence-activating cell sorting
(FACScan®) (Becton-Dickinson, Mountain
View, CA). Control cell suspensions were incu-
bated with nonspecific mouse IgG; whereas, T-
cell enrichment was evaluated by gating each
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cell preparation by both FITC-anti-CD45 and
PE-anti-CD14 (Becton-Dickinson), which re-
vealed less than 1.2% monocyte contamina-
tion. Each analysis included a total of 10,000
events. Aliquots were used to set up
T-cell cultures from both patients and controls.
T-cell cultures were started in plates at 1 
106/ml in RPMI-1640 plus 10% fetal calf serum,
10 g/ml PHA and interleukin-2 (IL-2), and
maintained for up to 72 hr in the presence of
two 8-mer synthetic peptides resembling the
flank regions of VEINCTR–N (7), namely pep-
tide (pept.) #1 (CDEGHGLE) and pept. #2
(TKCRCKPN), in addition to VEINCTR–N it-
self, and native human sFas (Alexis Corpora-
tion, San Diego, CA). The synthetic peptides, as
well as the recombinant sFas, were filtered to
avoid any contamination and were endotoxin-
free as a result of the purification procedure by
high performance liquid chromatography
(HPLC) (7). Each peptide was separately added
to cell cultures at various concentrations 
(10, 25, and 50 g/ml) to measure the dose-
dependent effect; whereas, sFas was used at
lower amounts (0.1, 1, 5, and 10 g/ml). Paral-
lel experiments evaluated the effect of both Fas-
related peptides and the full-length sFas on Fas-
positive cell lines that included both Jurkat and
CEM cells (American Type Culture Collection
(ATCC), Manassas, VA) as models of human T
cells of clonal origin, and the mouse WR19L cell
transformant overexpressing Fas (32). As Fas-
negative cell controls, we used both K562 and
Daudi, and the native WR19L as human and
mouse cell lines, respectively. Several of them
were also used in subsequent tests to avoid the
potential heterogeneity of T-cell cultures from
both patients and donors, since they were not
clonally obtained.
Evaluation of Proliferation and Apoptosis
Aliquots of cells were recovered from the pep-
tide- and sFas-stimulated cultures after 24, 48,
and 72 hr of incubation and their proliferation
and apoptosis were measured. Suitable control
cultures were also provided by unstimulated
cell suspensions. In addition, the sFas-
stimulated cultures were paralleled by control
cell preparations additionated with sFas prein-
cubated for 90 min, with the mouse IgG anti-
Fas MoAb from clone ZB4 (Immunotech, Mar-
seille, France) at 10 g/ml, as an attempt to
neutralize its binding. Proliferation was deter-
mined by evaluating both the 3H-thymidine
uptake and Ki67 antigen expression in cultures
and cell lines. 105 cells from each preparation
were incubated overnight in the presence of
3H-thymidine (7400 Bq per well). The prolifer-
ation rate was assessed with a -counter (Beck-
man, Palo Alto, CA) and calculated according
to previously standardized experiments as a
percentage of 3H-thymidine incorporation or
inhibition of proliferation (31). A parallel cyto-
fluorimetric assay investigated the expression of
Ki67 by a FITC-conjugated MoAb (MIB-1 clone;
Immunotech) after treatment with 50 g/ml
digitonin (Sigma, St. Louis, MO) to improve the
cell membrane permeability. Lastly, Ki67 ex-
pression on viable cells gated by their scatter pa-
rameters, was analyzed by the Cell Quest pro-
gram in the FACScan® (Becton-Dickinson).
Apoptosis was initially assessed by cytoflu-
orimetric measurement of cell populations with
subdiploid DNA peak by propidium iodide
(PI) as described (31). Aliquots of cell prepara-
tions were also examined in parallel with the
APO2.7 MoAb to a 38 kDa mitochondrial pro-
tein, which is regarded as an early apoptosis
marker, since viable cells were negative or
weakly positive (33). Its expression was as-
sessed by flow cytometry using the permea-
bilizing protocol with digitonin and the PE-
conjugated APO2.7 (Immunotech). In some 
instances, apoptosis was also evaluated by the
terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL; Promega, Madison,
WI), and by the annexin-V fluorescence assay
(Boehringer-Mannheim, Milan, Italy).
Detection and Analysis of Cytoplasmic Free Calcium
The degree of cell activation was also deter-
mined by analysis of cytoplasmic free Ca2 in re-
sponse to stimulation by either sFas or its pep-
tides, according to Vanderberghe and Ceuppens
(34), with fluo-3 as the fluorescent indicator of
Ca2. Briefly, Jurkat, WC8, and WR19L cells
were pretreated for 1 hr with fluo-3 at a final
concentration of 4 M. They were then washed
three times, resuspended in a N-2-hydroxyethyl
piperazine-N-2-ethanesulfonic acid (HEPES)-
buffered solution, at pH 7.4, containing 1 mM
CaCl2, 0.5 mM MgCl2, and bovine serum albu-
min (BSA), and stimulated with sFas and pep-
tides, and with the CH11 anti-Fas MoAb (Im-
munotech) as control, for 15, 45, and 75 min.
Furthermore, the suspensions were analyzed
discontinuously in their events in the FACScan®
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by the Cell Quest software (Becton-Dickinson),
and the data were compared with the unstimu-
lated control preparations.
Measurement of Fas-L Cell Expression and Release
The expression of Fas-L in cell preparations was
improved by treatment with EDTA to inhibit the
shedding of Fas-L by cell membranes (35);
whereas, its release in the supernatants was as-
sessed by ELISA (36). Cells were first incubated
with the biotin-conjugated anti-Fas-L MoAb
from NOK-1 clone (PharMingen, San Diego,
CA) and then treated with streptavidin-FITC
(Sigma) prior to their cytofluorimetric analysis
in the FACScan®. Furthermore, we measured
the expression of Fas-L mRNA in cell lines stim-
ulated with both VEINCTR–N and sFas by mol-
ecular biology tests (37). mRNA was isolated by
the guanidium thiocyanate-cesium chloride pro-
cedure (Invitrogen, Celbio, Pero, Italy), and
transcribed into first-strand cDNA with the
Boehringer-Mannheim kit. The Fas-L wild-type-
specific primers were designed in relation to the
known gene structure as follows: 5-GCC CAA
GCT TGA AGC AGC CCT-3 (FW), and 5-TGC
TGT GTG CAT CTG GCT GGT AGA-3 (RV) re-
lated to exon-2 of the gene. Both primers and
cDNA from cell lines were added to the poly-
merase chain reaction (PCR) mixture (Perkin
Elmer Biosystems, Foster City, CA), with subse-
quent amplification in a thermal cycler for 35 cy-
cles (30 sec at 94C; 30 sec at 65C; and 30 sec at
72C). The Fas-L PCR product was visualized on
agarose gel with ethidium bromide. It was then
measured by evaluating the bands as “trace
quantity value” optical density (O.D.  mm of
each band) with the Quantity-One 4.3 software
in the Fluor-S MultiImager gel analyzer (Bio-
Rad Labs, Hercules, CA). For semiquantitative
analysis, graded amounts of cDNA obtained
from the same tube were used in parallel PCR
experiments to obtain a linear reference curve; 
-actin also was included as internal control
(FW: 5-GAC CAT CAC GAT GCC AGT GGT 
A-3; RV: 5-GAT CAT GGA TGA TGA TAT
CGC-3). Lastly, the ELISA measuring the secre-
tion of Fas-L in the supernatants from the same
cell preparations was optimized by using two
MoAbs to different epitopes of Fas-L, namely
NOK-1 and NOK-2 (PharMingen). The test was
completed as previously described (36).
Evaluation of Caspase Activation
We also explored by different approaches the
activation of three caspases to determine
whether apoptosis induced by VEINCTR–N
and sFas was promoted by activation of the
membrane-bound Fas. Cytosolic extracts were
prepared by homogenizing cell pellets in 10
mM HEPES/KOH (pH 7.4), 2mM EDTA, 0.1%
(3-[(3-cholamidopropyl) dimethylammonio]-l-
propane-sulfonate (CHAPS), 5mM DL-Dithio-
threitol (DTT), 1 mM phenyl-methylsulpho-
nylfluoride, 10 g/ml pepstatin A, 20 g/ml
leupeptin and 10 g/ml aprotinin, and recover-
ing the supernatant after centrifugation at
14,000  g (Sigma, St. Louis, MO, USA). The
extracts were run in SDS-PAGE, blotted in ni-
trocellulose, blocked with 2% BSA in phos-
phate-buffered saline (PBS) plus 0.05%
Tween-20, and separately incubated overnight
at 4C with a mouse MAb to caspase 8 (FLICE;
Biosource, International, Camarillo, CA), and
rabbit polyclonal antisera to caspase 3 (CPP32)
and caspase 1 (ICE; Biosource). Both poly-
clonal antisera were described by the manufac-
turer as able to detect the proenzymatic form,
as well as the cleaved subunits, of relative cas-
pases. The test was subsequently completed
with the peroxidase-coupled anti-mouse and
anti-rabbit IgG antisera, respectively. Both
proenzymatic caspases and subunits were 
revealed on blots by enhanced chemilumines-
cence, according to the manufacturer’s instruc-
tions (Amersham International, Bucking-
hamshire, England).
A second method measuring caspases acti-
vation included a colorimetric assessment of
their cleaved subunits in the cytosolic extracts
from Jurkat cells incubated for 48 hr with
those apoptosis inducers. We used specific
substrates for CPP32 and ICE, according to the
manufacturer’s protocol (Alexis). Briefly, 
100 l of cell lysates in reaction buffer (100
mM HEPES pH 7.5, 10% sucrose, 0.1%
CHAPS, 10 mM DTT, 0.1 mg/ml ovalbumin)
were incubated in 96-well plate for 3 hr at
37C, with 50 M of p-Nitroanilide (pNA)-
conjugated-specific four-amino-acid substrates
for caspase 3 and 1 (DEVD-pNA and YVAD-
pNA, respectively). Each determination was
performed in triplicate and relative ab-
sorbance was measured at 405 nm in a (Bench-
mark) microplate reader (Bio-Rad Labs, Her-
cules, CA).
Molecular analysis of caspase expression
was also completed by RT-PCR measurement
of relative mRNA. In addition to Jurkat cell
preparations treated with sFas, VEINCTR–N,
and CH11 MoAb as positive control of the Fas
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activation pathway, we included a parallel cell
suspension incubated with TNF at the func-
tional dose of 10 ng/ml as a positive control to
look for any discrepancy in expression be-
tween the Fas and the TNF pathways. The
mRNA from Jurkat cells incubated overnight
with CH11, sFas, VEINCTR–N, or TNF, and
from untreated control cells was then amplified
in a thermal cycler by the RT-PCR method. The
primers were designed according to the gene
structure of each caspase (38–40) as follows:
ICE (casp. 1) 5-GCA CAC GTC TTG CTC TCA
TTA TCT G-3 (FW), and 5-GGC TGC TCA
ADT GAA AAT CGA ACC-3 (RV); CPP32
(casp. 3) 5-TGG TAC AGA TGT CGA TGC
AGC-3 (FW), and 5-TGC CAC AGT CCA GTT
CTG TAC C-3 (RV); and FLICE (casp. 8) 
5-TGA GCT GAC ATC TCA GTT CAC TGG 
T-3 (FW), and 5-TGT GAA AGT AGG CTG
AGG CAT CTG-3 (RV). The amplification was
completed by standard procedures using 35 cy-
cles (60 sec 94C; 60 sec 60C; and 60 sec 72C)
and semiquantitative analysis of mRNA on the
agarose gel was assessed as the trace quantity
value for each determination by the Fluor-S gel
analyzer (Bio-Rad Labs). Graded amounts of
cDNA of each caspase were also amplified to
provide relative reference curves in addition to
the -actin measurement.
Statistical Analysis
Mean values of cellular marker expression and
proliferation between groups were compared
with Student’s t-test. The distribution of sub-
diploid DNA content in both stimulated and
unstimulated cultures was also assessed in a
few instances by the Wilcoxon test as a non-
parametric method.
Results
Effect of sFas and Its Peptides on T-cell Culture
Proliferation and Apoptosis
The first set of experiments addressed the ques-
tion whether VEINCTR–N, its contiguous 8-mer
stretches, and sFas interfered with the repli-
cation of T cells. The proliferation rate of T-cell
cultures stimulated with these protein fragments
was compared with the 3H-thymidine incorpora-
tion of unstimulated cultures from both patients
and controls whose individual values were con-
sidered as reference levels of proliferation (100%
of 3H-thymidine uptake). In preliminary experi-
ments, we assessed the dose-response kinetics
by using different amounts of these stimulators.
An appreciable response was recorded with a
concentration of 25 g/ml, though 50 g/ml of
each peptide produced the greatest effect. By
contrast, sFas was found to optimize its response
at 5 g/ml. Therefore, we adopted these concen-
trations and Figure 1 shows the time-dependent
results. As depicted, a major suppression was
observed after 48 hr (Fig. 1A). VEINCTR–N,
however, induced a higher degree of inhibition
at a magnitude similar to sFas, since the mean
values of 3H-thymidine uptake dropped to about
40%. A lower, though significant (p  0.1),
suppression (about 50%) also occurred in cul-
tures treated with pept. #2; whereas, pept. #1 in-
duced a lower inhibitory effect, even after 72 hr
of incubation. We observed a slightly different
response in cultures from uninfected individu-
als. Almost all cell preparations but those sFas-
treated, were insensitive to the peptides and
showed a minor inhibition, even with the pro-
gression of the incubation. By contrast, the mean
values of suppression obtained in sFas-incu-
bated cultures revealed a significant inhibition
(p  0.03), compared with those induced by the
peptides, since the inhibitory effect was nearly
equivalent to those recorded in the suppressed
cultures from patients. However, the sFas inhib-
ited by preincubation with ZB4 MoAb was re-
vealed to be ineffective for inducing a similar ex-
tent of suppression in both groups of cultures.
sFas- and peptide-incubation also induced
a variable extent of apoptosis. A prevalent in-
crease was observed in cultures incubated
with both VEINCTR–N and sFas. This effect
was persistently evident after 48 hr in most
patient cell preparations and to a lesser degree
in those from the controls. The subdiploid cell
population was almost doubled following in-
cubation with VEINCTR–N or sFas. Figure 1B
shows the cytofluorimetric PI staining of the
apoptotic cells in representative patterns from
patient #11 and a normal donor (#7). As can
be seen, both VEINCTR–N and sFas induced a
remarkable increase of the M1 peak, which in-
cluded the subdiploid-DNA-containing cells
in either the patient (upper panels) or the con-
trol (lower panels). Data from the other pa-
tients and controls revealed a prevalent pat-
tern of amplification of this population in
response to either sFas or VEINCTR–N, with
significant differences in increments (p  0.02
in both groups). By contrast, no appreciable
variation of the extent of apoptosis was
recorded in cultures incubated with either
pept. #1 or #2.
Fas-positive Cell Lines are Sensitive to VEINCTR–N
and sFas-mediated Suppression
Since the patients and control cell cultures were
not clonally expanded and included heteroge-
neous T cells at various differentiation steps,
we reasoned that optimization of the effect of
these soluble inhibitors on clonal models of 
T-cell lines could emphasize their apoptogen-
potential. Therefore, we set up several assays
with Jurkat and CEM as Fas-positive human 
T-cell models, and with K-562 and Daudi as
Fas-negative controls. Figure 2A shows the 
effect on the proliferation of these cell lines.
Both Jurkat and CEM were significantly affected,
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Fig. 1. Suppression of peripheral T cells by
soluble molecular forms of Fas, including the
full-length receptor (sFas), and sequential 
8-mer peptides structurally related to its first
consensus sequence including VEINCTR–N, an
immunogenic epitope. (A) Prevalent inhibition of
the proliferative rate was observed after 48 hr in 
T-cell cultures from 16 human immunodeficiency
virus-type 1 (HIV-1)-infected individuals (full 
symbols) selected from a group of patients with
serum elevations of both anti-VEINCTR–N 
immunoglobulin G (IgG) and soluble Fas (sFas),
and increased extent of T-cell apoptosis (7). Inhibi-
tion of 3H-thymidine uptake was significant in 
cultures treated with either sFas or VEINCTR–N 
(p  0.02 in all instances), and in those with pept.
#2 (p  0.1), compared with relative control
unstimulated cultures whose values of 3H-thymi-
dine uptake were referred as 100% of proliferation.
Control T-cell cultures from 15 uninfected subjects
(empty symbols) were inhibited prevalently by
sFas, though to a lesser degree. Such a suppressive
effect of sFas was abolished in control cultures by
its preincubation with ZB4 MoAb. Values are ex-
pressed as percentages of 3H-thymidine uptake. 
(B) Cytofluorimetric patterns of apoptosis induction
by both sFas and VEINCTR–N in peripheral T cells
from an HIV-1-infected patient (upper panels) and
a normal donor (lower panels), measured as varia-
tion of M1, namely the subdiploid DNA-containing
cell population, following propidium iodide 
staining. A significant increase of M1 occurred at
48 hr of culture in cells treated with either sFas or
VEINCTR–N, compared with untreated control
cells (p  0.02 in both groups of experiments). 
By contrast, pept. #1 and #2 failed to induce appre-
ciable changes in most cell preparations.
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Fig. 1. (Continued)
compared with their control lines. A major sup-
pression was detected in cell preparations incu-
bated with either VEINCTR–N or sFas, whose
average inhibition after 48 hr increased to about
60% and 40% in Jurkat and CEM cultures, re-
spectively (p  0.02 in both instances). A mi-
nor effect was also recorded for pept. #2, which
restrained their proliferation by about 40% and
30%. Conversely, a minimal inhibition was in-
duced by pept. #1, as in the patient cultures;
whereas, the proliferation of both K-562 and
Daudi remained unaltered. These results sug-
gested that the occurrence of Fas on the cell
membrane could be essential for down-modu-
lating proliferation in the presence of sFas and
its peptides. However, we also measured their
effect on the proliferative extent of WC8, namely
the human Fas-transfected mouse lymphoma,
and its negative control, WR19L (32). WC8 was
inhibited in the same way by either VEINCTR–N
or sFas (Fig. 2B), though to a lesser degree than
Jurkat and CEM; whereas, similar to the Fas-
negative human cell models, the proliferation
of WR19L was not influenced. This finding
postulated the hypothesis that the membrane
expression of Fas could be involved with driv-
ing the suppressive effect of sFas and its func-
tional peptide. To support the suspected agonist
effect of sFas, the Fas-positive control cultures
treated with the soluble receptor pre-inhibited
by ZB4 MoAb were not affected in their prolif-
erative extent.
Further experiments explored whether the
decreased uptake of 3H-thymidine in the pres-
ence of sFas and related peptides was attribut-
able to specific inhibition of proliferation or
enhancement of apoptosis by investigating in
parallel the expression of both Ki67 and the
APO2.7–related mitochondrial antigen. Figure 2C
shows the cytofluorimetric pattern of both
Jurkat and CEM cells. In both instances, the ex-
pression of these markers differed in relation to
the presence of sFas or its functional peptides.
In control untreated cultures, the Ki67 positive
cells, namely M2 populations, showed high val-
ues of fluorescence intensity and were more
than 50% as in those supplemented with pept.
#1. However, the mitochondrial protein was
scarcely expressed (M2  7.5%). By contrast,
incubation with VEINCTR–N lowered the M2
Ki67 peaks to 22.5% and 20.2% for the two cell
lines, respectively. An analogous effect was also
detected in cultures treated with sFas. Con-
versely, a different pattern of the mitochon-
drial protein expression was recorded, since
VEINCTR–N raised the APO2.7-positive popula-
tion to 73.1% and 54.1% in Jurkat and CEM
cells, respectively; whereas, sFas induced a simi-
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creased the relative M2 peaks, namely the cells
exposing phosphatidylserine as the effect of
membrane disruption by apoptosis. This popu-
lation was expanded significantly (p  0.02 in
all instances) in such models of Fas-positive
cells, with respect to the relative control un-
treated cultures. By contrast, the K-562, Daudi
and WR19L control lines failed to show an ap-
preciable M2 peak increase (data not shown).
VEINCTR–N and sFas Activate Cytoplasmic Ca2
Activation of Jurkat, WC8 and WR19L cells in
response to sFas and its peptides also was
measured from the variation of their intracellu-
lar accretion of this population. Such a signi-
ficant increase of the APO2.7-reactive antigen 
(p  0.03) in cells with defective presence of Ki67
suggested that the major effect of sFas and its 
active peptide was the actual induction of apop-
tosis, rather than inhibition of T-cell proliferation.
This suggestion was also supported by the
demonstration of enhanced levels of annexin-V
on the cell membrane in the same cultures main-
tained up to 24 hr. Figure 2D illustrates this
cytofluorimetric profile in both Jurkat and CEM
cells. We also measured the effect of stimulation
by sFas and related peptides on the annexin-V
expression of WC8 cells. Once again, incubation
with either VEINCTR–N or sFas dramatically in-
Fig. 2. Percent inhibition of the in vitro prolif-
erative rate in human and mouse T-cell lines.
Human (A) and mouse (B) T-cell lines were 
measured by 3H-thymidine uptake in the presence
of sFas and its soluble peptides. Major inhibition
occurred in Jurkat and CEM cells treated with the
full-length soluble receptor and with VEINCTR–N,
compared with the control untreated cells. Pept. #2
also moderately inhibited both lines. The human
Fas-transfected mouse T-cell lymphoma, WC8, also
was suppressed significantly by both sFas and
VEINCTR–N; whereas, the proliferation of human
(K-562 and Daudi) and mouse (WR19L) 
Fas-negative cell lines was not influenced. The
preincubation of sFas with the ZB4 MoAb anti-Fas
neutralized its inhibitory effect on cell prolifera-
tion. (C) Cytofluorimetric measurement of both
Ki67 and APO2.7-related antigens as markers of
proliferation and apoptosis, respectively. Jurkat
and CEM cells were incubated overnight with the
soluble molecular forms of Fas and, then, evaluated
in parallel for their expression of both antigens in
relation to control cultures. Although the
suppressive effect of VEINCTR–N and sFas on both
cell lines induced a variable decrease of the Ki67-
positive population (M2), a significant expansion
of the apoptotic subset occurred, since the APO2.7-
positive M2 extent in both Jurkat and CEM prepa-
rations was greatly increased by both inhibitors 
(p0.02 in all instances). Conversely, pept. #1 and
#2 only induced a minor variation of Ki67 expres-
sion. (D) Measurement of apoptosis in Fas-positive
cell lines by detection of annexin-V. The apoptotic
population (M2) was expanded in Fas-positive cell
lines of either human (Jurkat and CEM) or mouse
(WC8) origin, predominantly in cultures supple-
mented with VEINCTR–N or with sFas, compared
with relative untreated control cultures (p  0.02).
The other soluble peptides of Fas resembling the flank
regions of VEINCTR–N failed to induce a similar 
effect. sFas, soluble Fas; pept., peptide.
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Fig. 2. (Continued)
lar Ca2 content. We used fluo-3 staining and
evaluated the events in a discontinuous man-
ner. However, comparison of the data at inter-
vals following this treatment provided appre-
ciable differences 30 min after stimulation.
Table 1 shows both the percentage of positive
cells to the free cytoplasmic Ca2 and the mean
fluorescence variations. A variable increase of
both parameters always was observed, espe-
cially in both Fas-positive cell lines incubated
with either VEINCTR–N or sFas. Expansion of
the subset related to fluo-3-retaining cells was
associated with a parallel increase of the fluo-
rescence intensity, whose three-times-higher
values were almost equivalent to those ob-
tained with the CH11 anti-Fas MoAb. By con-
trast, the Fas-negative WR19L cells remained
unaffected, since no valuable variations of
either percentage or fluorescence intensity
of positive cells were detected. These data
provided definite evidence that sFas and
VEINCTR–N induce an appreciable cell activa-
tion, based on the accretion of cytoplasmic free
Ca2 to an extent comparable to that elicited by
the agonist anti-Fas MoAb.
Fas-L Expression and Secretion are Influenced by sFas
Since sFas and VEINCTR–N induced the apop-
tosis of both human and mouse Fas-positive cell
lines, we investigated the involvement of Fas-L
with priming the death process in those cells.
We measured both the membrane expression of
Fas-L by flow cytometry and its release in su-
pernatants as the effect of its shedding after
overnight incubation with both apoptosis in-
ducers. Preliminary assays showed considerable
solubilization of the ligand in culture medium
and feeble detection on cell membrane. There-
fore, we evaluated both Fas-L expression and
secretion in cells cultured in the presence of
EDTA to prevent the effect of metalloproteinases
(35). In addition, we measured the Fas-L mRNA
by RT-PCR in the same cell preparations. Figure
3A shows the results of membrane Fas-L ex-
pression on Jurkat, WC8, and WR19L cells
stimulated by either VEINCTR–N or sFas. Both
inhibitors induced an expansion of the Fas-L
positive population, which was increased
within the Jurkat and WC8 lines (p  0.03 in all
instances), in contrast with the stable levels of
Fas-L expression in the WR19L line. However,
although this percent increment of cells sug-
gested that both stimuli influenced Fas-L ex-
pression on many cells, the relative means of
fluorescence intensity showed a minimal in-
crease that could mean that EDTA was unable to
inhibit complete solubilization of the receptor.
Figure 3B (left graph) shows the results of
Fas-L detection and measurement in sFas-
stimulated Jurkat, WC8, and WR19L superna-
tants. The soluble form of Fas significantly 
increased the solubilization of Fas-L in super-
natants of cultures from Jurkat and WC8 cells,
compared with untreated cells (p  0.02 in all 
instances); whereas, its basic secretion by WR19L
remained unaffected. The EDTA-supplemented
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Table 1. Measurement of the effect of multiple peptides of Fas, sFas, and the apoptogen MoAb 
anti-Fas (CH11) on Fas positive (Jurkat and WC8) and negative (WR19L) cell lines, as variation of the
cytoplasmic free Ca2.
Jurkat WC8 WR19L
Positive Positive Positive
Cells Fluorescence Cells Fluorescence Cells Fluorescence
(%) (M) (%) (M) (%) (M)
Untreated cells 2.7 4.1 4.1 3.7 3.6 3.9
Cells  pept. #1 7.7 5.6 5.3 4.6 3.8 3.7
Cells  VEINCTR–N 29.1 12.7 25.6 10.3 5.3 4.1
Cells  pept. #2 12.5 8.3 10.2 7.9 4.7 2.9
Cells  sFas 32.6 12.3 26.1 10.4 5.8 4.0
Cells  CH11 29.9 11.8 23.2 11.2 3.9 3.7
The analysis was completed by flow cytometry 30 min after staining the pretreated cells with fluo-3, a fluorescent indicator of
Ca2. Data are presented as both percentage of fluo-3 positive cells and mean of fluorescence intensity (M) in each cell 
preparation. M, mean of fluorescence intensity; sFas, soluble Fas.
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Fig. 3. Induction of Fas-L expression by both
VEINCTR–N and sFas. (A) Cytofluorimetric
measurement of membrane-bound Fas-L in Jurkat,
WC8, and WR19L cells after treatment with those
inhibitors. The cells were incubated in the presence
of EDTA to prevent shedding of the ligand by
metalloproteinases. Both Jurkat and WC8 almost
doubled their Fas-ligand (Fas-L)-positive subsets;
whereas, the control Fas-negative WR19L cells were
not influenced. (B) (left graphic) Detection of Fas-L
release in supernatants from Jurkat, WC8, and
WR19L cells incubated overnight with 5 g/ml of
soluble Fas (sFas). A significant increase of
sFas-L was revealed in culture media from both
Jurkat and WC8, compared with untreated control
cells (p  0.02), in contrast with the defective
response of WR19L cells. As expected, parallel
control cell preparations stimulated by sFas in the
presence of EDTA maintained a low level of Fas-L
shedding. (right graphic) Measurement of Fas-L
mRNA by RT-PCR in Jurkat cells treated with
CH11, sFas, and VEINCTR–N. Analysis by the
Fluor-S MultiImager gel analyzer confirmed a
variable, though significant, Fas-L mRNA increment
(p  0.03) in response to the overnight incubation
with sFas, VEINCTR–N, or CH11, compared with
untreated control cells. By contrast, no difference of
-actin mRNA expression was observed.
O.D., optical density.
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control cultures showed a moderate release of
Fas-L, due to membrane inhibition of sFas-L
shedding. In line with the flow cytometry data,
these results emphasized the persistence of 
Fas-L membrane expression on cells cultured
with EDTA and supported the hypothesis that
sFas acted as a Fas-L inducer in these cell lines.
Fas-L mRNA measurement in Jurkat cells
treated with CH11, sFas, and VEINCTR–N is il-
lustrated in the right graphic of Figure 3B.
When preparing these experiments, we found a
different time-course effect in relation to the
stimulator used. In particular, CH11 provided
complete induction of apoptosis in T-cell lines
within 5 hr; whereas, sFas, as well as its pep-
tides, required at least an overnight incubation
to obtain an appreciable variation of Fas-L ex-
pression. However, measurement of mRNA
was completed following treatment with each
stimulator. Semiquantitative evaluation by the
Fluor-S gel analyzer confirmed the increase of
Fas-L expression observed by flow cytometry,
since high trace quantity values were de-
tectable in PCR products from cells incubated
with either sFas or VEINCTR–N. The linearity
of semiquantitative PCR was determined for
each condition using graded (0, 0.1 l, 2, 4, 8)
amounts of cDNA (data not shown). The Fluor-
S trace quantity values in treated cells were
1.607 and 1.438, respectively, compared with
0.891 for the control unstimulated cells. The
statistical interpretation of these data sug-
gested that a significant difference occurred be-
tween both values of mRNA levels in cells
treated with either VEINCTR–N or sFas, com-
pared with unstimulated cells (p  0.03 in both
instances), though the difference with CH11
was higher (p  0.02). As expected, the -actin
used as an internal control of the assay was
uniformly expressed by both control and stim-
ulated cells. These results suggested that a vari-
able expression of Fas-L occurred in response
to these stimulations.
CPP32 and FLICE are Activated by Both sFas
and VEINCTR–N
Determination of whether the Fas pathway of
Jurkat, as a model of Fas-positive T cells, was
involved in the apoptosis following the treat-
ment with either sFas or VEINCTR–N was
lastly sought by measuring caspase activation
in this line. Immunoblotting of the cell extract
and semiquantitative measurement of mRNA
assessed the expression of caspase 8 (FLICE),
which was part of the receptor complex trans-
ducing the death signal in response to Fas
oligomerization. The activity of caspase 3
(CPP32), which is directly induced by FLICE,
and caspase 1 (ICE), which defines activation
of the TNF pathway in transduction of the
death signal, also was explored. Jurkat cells
were separately incubated overnight with sFas,
VEINCTR–N, and CH11 MoAb. The cell ex-
tracts were used as substrate in immunoblot-
ting. The colorimetric measurement of cleaved
Fig. 3. (Continued)
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subunits of both CPP32 and ICE was also as-
sessed in parallel.
We also completed this analysis by the 
RT-PCR measurement of each caspase mRNA
extracted from a parallel set of cell prepara-
tions, including a control cell suspension treated
with TNF. Results are shown in Figure 4. The
chemiluminescence detection of caspases (left
graphics) showed a variable expression of their
proenzymatic forms. Both sFas and VEINCTR–N-
treated cells were found to express the native
caspases, in particular CPP32 and FLICE, at
higher intensity than the control cell prepara-
tion. We also observed in these cell extracts the
12.0 kDa subunits of CPP32 as expression of its
cleaved form, as observed in the CH11-
supplemented culture. The MoAb to FLICE
only revealed the proenzymatic form, since it
was unreactive to cleaved subunits. However,
an apparent increase of its intensity was
recorded in cells treated with either sFas or
VEINCTR–N, compared with control untreated
cells. By contrast, no evidence of ICE activation
was detected on the blotted extracts (data not
shown).
RT-PCR (Fig. 4, right graphics) also illus-
trates the variable expression of both CPP32 and
FLICE mRNAs in Jurkat cells treated with sFas
Fig. 4. CPP32 and FLICE expression in Jurkat
cells, in response to treatment with sFas and
with VEINCTR–N. (Left graphics) Immunoblot-
ting of cell extract shows the increased expression
of both CPP32 (upper graphic) and FLICE (lower
graphic) and the presence of cleaved CPP32. Rabbit
antiserum to CPP32 detected the 12.0 kDa active
subunit of that protease in cultures treated with
both soluble forms of Fas. Mouse MoAb to FLICE
also revealed in these cultures the proenzymatic
form in amounts comparable to that induced by
CH11. Control untreated cells showed defective
expression of either native or activated enzymes.
Numbers refer to molecular weight (m.w.) (Right
graphics) – CPP32, FLICE, and ICE mRNA analysis
by reverse transcription polymerase chain reaction
(RT-PCR) in Jurkat cells incubated with either
soluble Fas (sFas) or VEINCTR–N, compared with
treatment with CH11 and tumor necrosis factor 
(TNF). Both CPP32 and FLICE mRNA were
expressed variably in cells treated with these
soluble forms, compared with the control untreated
cells. The semiquantitative Fluor-S evaluation
revealed an increase of relative trace quantity 
values in apparent concordance with those detected
in the control cell preparations treated with either
CH11 or TNF. By contrast, ICE was only expressed
by cells supplemented with TNF, suggesting that
suppression of Jurkat cells in cultures treated with
either sFas or VEINCTR–N was mediated by their
Fas-pathway activation. As expected, the -actin 
expression as internal control, was not influenced.
Numbers are bp size.
and VEINCTR–N, compared with positive (CH11
and TNF) and negative (untreated cells) con-
trols. Both caspases apparently were increased
with respect to their negative control, though to
a lesser extent than in CH11 and TNF-treated
cultures. The trace quantity values were 2.446
and 2.107 for CPP32, and 1.231 and 1.101 for
FLICE. These increases resembled those ob-
tained by the CH11 stimulation (CPP32: 2.547;
FLICE: 2.815), suggesting that Fas was activated
by the soluble forms of the receptor. By contrast,
RT-PCR failed to demonstrate an equivalent ac-
tivation of ICE. The mRNA related to this pro-
tease was not enhanced with respect to the neg-
ative control; whereas, it was clearly expressed
in the cell preparation supplemented with TNF
(O.D.  mm: 1.947). The differences obtained by
this semiquantitative measurement were in agree-
ment with the values of the reference curves;
whereas, the -actin control revealed a uniform
amplification of relative cDNA in cultures.
Lastly, the presence of cleaved CPP32 in
cytosolic extracts of both sFas- and VEINCTR–
N-treated cells was confirmed by the colorimet-
ric method using pNA-conjugated substrates.
Table 2 shows the results in O.D. values at 405nm.
These were almost doubled in cells cultured in
the presence of soluble forms of Fas and paral-
leled the values detected in control assays us-
ing either CH11 or TNF. Once again, this test
failed to prove the presence of activated
cleaved subunits of ICE in cells incubated with
sFas and VEINCTR–N, thus, providing definite
evidence that both soluble molecular forms of
Fas were apoptosis-inducers through the Fas
pathway.
Discussion
The present study demonstrates that soluble
molecular forms of Fas that include sFas or its
major immunodominant domain VEINCTR–N,
which are located in a consensus sequence
shared by other members of the TNF receptor
family, are actual inducers of apoptosis in vitro
in peripheral T cells from both HIV-1-infected
patients and controls, as well as in lympho-
blastic Fas-positive T-cell lines. These findings
lead to reconsidering the biological role of the
soluble forms of Fas, whose serologic eleva-
tions during the course of HIV-1 infection
(2,9–13) and in autoimmune diseases (17,21,
22) have been postulated to disable Fas-L of ef-
fector cells within the immune system, result-
ing in down-regulation of apoptosis (27,29).
By using a proliferative assay, we found
that most T-cell cultures from HIV-1-infected
subjects showing high serum levels of anti-
VEINCTR–N reactivities and from a control
group were significantly inhibited by either
sFas or VEINCTR–N. However, the main effect
was a clear-cut induction of apoptosis, since
the subdiploid DNA-containing cell popula-
tion was expanded. Similar suppression was
also detected in experiments using clonotypic
T-cell lines of both human, such as CEM and
Jurkat, and mouse origin, namely a WR19L
transformant overexpressing Fas (32). By con-
trast, the proliferation of Fas-negative cells in-
cluding K-562, Daudi (40), and WR19L was
not affected.
That induction of apoptosis was the pre-
dominant element of this suppression also was
indicated by overexpression of both a mito-
chondrial protein detected by the APO2.7
MoAb as an early apoptosis marker, and an-
nexin-V in Fas-positive cell lines. Since the
presence of the membrane-bound form of Fas
appeared to be critical in this induction, we in-
vestigated the activation of several components
along the Fas pathway in both Jurkat and the
human Fas-transfected mouse lymphoma
WC8, treated with those soluble effectors. Fas-
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Table 2. Absorbance in optical density (O.D.) values at 405 nm of the enzymatic activity of cleaved
isoforms of both caspase 3 and 1 in Jurkat cells.
CPP32 ICE
Untreated 0.390  0.072 0.359  0.019
Cells  VEINCTR–N 0.788  0.068 0.473  0.052
Cells  sFas 0.770  0.084 0.421  0.023
Cells  CH11 0.828  0.052 0.398  0.061
Cells  TNF 0.807  0.037 0.889  0.044
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L mRNA apparently was up-regulated in both
cell lines, since a considerable secretion of the
ligand occurred in relative cultures. In addi-
tion, immunoblotting of cell extracts and RT-
PCR of mRNA from Jurkat cells revealed the
activation of proenzymatic CPP32 and FLICE
and, in several instances, their functional
cleaved subunits. These caspases are enrolled
in the death-inducing signaling complex
(DISC) activated by Fas (41). By contrast,
ICE, which is not involved in Fas-mediated
apoptosis (42,43), was only detectable in con-
trol cells treated in parallel with TNF. These
results also are confirmed by colorimetric as-
say showing the occurrence of cleaved iso-
forms of CPP32 in Jurkat cells treated with
either sFas or VEINCTR–N. Therefore, the
soluble molecular forms of Fas trigger the
apoptosis in cells overexpressing the receptor
and its shedding by chronically activated or
exhausted cells, as in HIV-1 infection, is per-
haps a mechanism entrusted with spreading
of a death outcome.
Recent studies have emphasized the role of
soluble receptors in modulating the functional
response of activated cells. Soluble forms of
receptors to several interleukins (44–46),
granulocyte-macrophage growth factors (47),
and TNF (18,19) have been described, but their
physiologic roles are still unclear. Soluble HLA
class I molecules deliver an apoptotic signal in
alloreactive CD8 T cells in the absence of a
second stimulus interacting with either TCR or
CD8 receptors (48). The molecular mechanism
implies up-regulation of Fas-L, resulting in the
autocrine activation of Fas pathway. It is
thought to protect against the rejection of an
organ transplant. However, serum sHLA class I
and II antigens also may be high in many
other conditions associated with the persistent
activation of the immune system. The detection
of high serum levels of these molecules in HIV-1
disease (49) supports the contention that
the autologous down-regulatory mechanism
demonstrated in organ recipients is also active
during retroviral infection and contributes to
the deregulated apoptosis of T cells. Since 
we found that the soluble molecular forms of
Fas were able to up-regulate both Fas-L ex-
pression and release by chronically activated
Fas-positive T-cell lines, it is conceivable that
induction of apoptosis is mediated by the au-
tocrine stimulation of their own Fas pathway,
just as sHLA molecules act in cell lines with a
constitutively high expression of Fas (48). We
confirmed the occurrence of this mechanism in
Jurkat cells incubated with either sFas or its
immunodominant epitope by the increase of
Fas-L mRNA, and both FLICE and CPP32 acti-
vation, including the cleavage in molecular
subunits as specifically observed in the Fas-
mediated transduction of death signals (50). In
this context, the detection of ICE mRNA and its
cleaved isoform only in TNF-treated Jurkat
cells provides a definite proof of the DISC
formation in cells undergoing apoptosis in
response to either sFas or VEINCTR–N.
A striking question raised by this study is
the effective role of these soluble forms of Fas
during the chronic immune activation ob-
served in both HIV-1 infection and other
diseases, including some autoimmune disor-
ders. Although previous studies have associ-
ated alternatively the serologic excess of sFas
with early (2,9) or advanced (10–13) HIV-1
infection, and to clinical activation of autoim-
mune derangements (17,21,22), the full-length
receptor and its splicing variants have been
seen as essentially apoptosis blockers or down-
regulators of cell death (27,29). In experimen-
tal models using truncated soluble forms of Fas
secreted by transfected COS cells (51), their
inhibition of apoptosis was ascribed to their
ability to block the agonist anti-Fas MoAb by
competitive affinity. However, their direct
effect on human Fas-positive target cells was
not investigated singularly in the absence of
the MoAb to Fas. In line with these studies,
our results suggest that, besides other regula-
tory effects, sFas directly interferes with its
membrane-bound homologous, resulting in au-
tocrine Fas-L-mediated suppression as a feed-
back-triggered response. This mechanism had
been suspected (51). We now provide evidence
of its effectiveness.
An unexpected result of our study is the
major suppressive effect induced on Fas-
positive human and mouse cell lines by the
synthetic peptide VEINCTR–N. This effect re-
sembles the immunodominant domain within
the highly conserved consensus sequence of
Fas. Although to a lesser extent than both full-
length receptor and the prototypic anti-Fas
agonist MoAb, the peptide induces sharp sig-
nals of apoptosis activation in target cells, such
as Fas-L and Fas-related caspases. Intracellular
calcium, as a universal second messenger mea-
suring the receptor activity, also is increased by
VEINCTR–N in Fas-positive cells, as in cell
preparations treated with either sFas or CH11.
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The evidence that VEINCTR–N induces Fas ac-
tivation independent of CD4 activation stems
from parallel experiments showing an equiva-
lent apoptogen effect on Jurkat cells by a form
of the peptide preincubated with soluble CD4
molecule (data not shown). Therefore, we ex-
plain VEINCTR–N-promoted apoptosis as the
result of the autocrine Fas-L secretion and/or
reverse stimulation of Fas by a mirror molecu-
lar mechanism involving peculiar domains of
functional receptors (51,52). This interpreta-
tion is in agreement with recent studies
demonstrating the specific activation of both
TNF and Fas by short peptides homologous to
their functional domains (53,54). On the other
hand, additional work has documented that
apoptosis can be induced directly in either
CEM or Jurkat cells by synthetic peptides that
are structurally identical to peculiar domains of
major histocompatibility complex (MHC) class
II and DR antigens, independent of the CD4
engagement (55). In this study, however, the
potential activation of Fas-pathway by such
peptides was not explored.
Another interesting aspect of this work
concerns the significance of anti-VEINCTR–N
antibodies in patients with progressing HIV-1
infection and serum elevations of sFas. When
we first detected antibodies to VEINCTR–N
(1,3), we thought they were elicited by the
gp120 V3 loop and became apoptosis effectors
following their cross-linkage with the mem-
brane-bound Fas on T cells. However, the
correlation with high levels of sFas, which may
also circulate in a structurally degraded form
overexposing the immunogenic epitope, sup-
ports the hypothesis that reactivities to the
full-length and molecular forms of Fas are
secreted in response to the high immunogenic-
ity of the receptor. The ability of VEINCTR–N
to evoke a cytotoxic response in vitro through
Fas in target cells, due to its antigenicity, has
been demonstrated by other investigators (56).
Although either anti-Fas or anti-VEINCTR–N
antibodies are realistic inducers of apoptosis in
vitro (1,2,20), it is presently unclear whether
they exert a role to neutralize the cytotoxic effect
of sFas and its functional domains in vivo.
In conclusion, our data provide a new
interpretation for the soluble molecular forms
of Fas. Although the shedding of Fas by acti-
vated cells is considered a survival mechanism
to disable Fas-L-positive effector cells and re-
sist apoptosis, in the first part of this work we
found that serum elevations of sFas in HIV-1-
infected patients with advanced disease paral-
leled both the extent of peripheral T-cell apop-
tosis and titers of anti-VEINCTR–N molecules.
Since apoptotic cells genetically are committed
to die by an irreversible program, it is conceiv-
able that the release of sFas is included in that
program as a mechanism to amplify the phe-
nomenon by spreading soluble effective forms
of the receptor. Although, in our studies the
suppressive effect of these molecular soluble
forms of Fas are demonstrated in vitro, we be-
lieve that a similar amplification event also
may occur in vivo, thus explaining the correla-
tion of high levels of sFas with the increased
extent of T-cell apoptosis in HIV-1 infection
patients. In this context, antibodies to struc-
tural domains of Fas would represent an
attempt to neutralize molecules involved in a
death execution program.
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